IMMP - Immutep Limited
| Previous Close | 2.0900 |
| Open | 2.1400 |
| Bid | 1.7800 x 1000 |
| Ask | 2.2500 x 4000 |
| Day's Range | 2.0400 - 2.1500 |
| 52 Week Range | 1.2700 - 3.2300 |
| Volume | 66,417 |
| Avg. Volume | 46,890 |
| Market Cap | 67.548M |
| Beta (5Y Monthly) | -0.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.39 |
- GlobeNewswire
Immutep Expands Part C of TACTI-002 Due to Positive Data
Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC)Part C has been expanded to include an.
- GlobeNewswire
INSIGHT-004 Clinical Trial Update
Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumabNo new safety signals in the first cohort, with 1 patient reporting a partial.
- Simply Wall St.
Those Who Purchased Immutep (ASX:IMM) Shares Five Years Ago Have A 31% Loss To Show For It
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...
- GlobeNewswire
Immutep Announces European Patent Grant for LAG525 Antibody
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “Antibody molecules to LAG-3 and uses thereof” by the European Patent Office. The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease. LAG525 is a humanised form of Immutep’s IMP701 antibody that was originally developed by Immutep S.A. (now Immutep S.A.S.), a wholly owned subsidiary of the Company.
- GlobeNewswire
Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reports positive interim data from its open label TACTI-002 Phase II clinical trial, building on the first top line data reported on 26 September 2019. It is evaluating the combination of Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in up to 109 patients with non-small cell lung cancer (NSCLC) in first and second line or second line head and neck squamous cell carcinoma (HNSCC).
- GlobeNewswire
Operational Update
TACTI-002 patient recruitment updateSix patients now enrolled and dosed in INSIGHT-004, 6 mg cohort completeSignificant eftilagimod alpha clinical data expected in coming.
- GlobeNewswire
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56%.
- Benzinga
The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
- Benzinga
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
- Simply Wall St.
Immutep Limited (ASX:IMM): When Will It Breakeven?
Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...
- GlobeNewswire
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
SYDNEY, Australia, Oct. 10, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
- GlobeNewswire
Immutep Announces Data Presentations at Upcoming Industry Conferences
SYDNEY, Australia, Oct. 10, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for.
- GlobeNewswire
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of.
- GlobeNewswire
Immutep to Receive £4M Milestone Payment From GSK
SYDNEY, Australia, Sept. 23, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments.
- GlobeNewswire
Immutep Announces Japanese Patent Grant for LAG525 Antibody
NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease. LAG525 is a humanised form of Immutep’s IMP701 antibody that was originally developed by Immutep S.A. (now Immutep S.A.S.), a wholly owned subsidiary of the Company.
- Simply Wall St.
Does Immutep Limited's (ASX:IMM) CEO Pay Reflect Performance?
Marc Voigt has been the CEO of Immutep Limited (ASX:IMM) since 2014. First, this article will compare CEO compensation...
- GlobeNewswire
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
SYDNEY, Australia, Aug. 22, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
- GlobeNewswire
Immutep Completes A$6M Entitlement Offer
NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the completion of its fully underwritten pro rata non-renounceable entitlement offer (“Entitlement Offer”) of new fully paid ordinary shares in Immutep (“New Shares”) which closed at 5.00pm AEST on Tuesday, 30 July 2019. The Entitlement Offer allowed eligible shareholders the opportunity to subscribe for one New Share for every 11.8 existing Immutep shares held as at the record date. Applications from eligible retail shareholders under the Entitlement Offer (including applications for additional New Shares in the shortfall facility, up to A$20,000) totalled 129,580,499 New Shares at A$0.021 per New Share.
- Benzinga
The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
- GlobeNewswire
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
NEW YORK, July 09, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “Company”), an Australian biotechnology company developing novel immunotherapy treatments for.
- ACCESSWIRE
Edison Issues ADR Update On Immutep (IMMP)
LONDON, UK / ACCESSWIRE / July 2, 2019 / Immutep's AIPAC Phase IIb study of its antigen-presenting cell activator eftilagimod alpha (efti) plus chemotherapy in breast cancer is fully recruited and expected ...
- GlobeNewswire
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
226 patients with metastatic breast cancer have been enrolled in the AIPAC studyCombination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in.
- GlobeNewswire
Immutep to Host Key Opinion Leader Call
NEW YORK, June 24, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer.
- GlobeNewswire
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
SYDNEY, Australia, June 21, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
